Nutriband Advances Abuse-Deterrent Drug Delivery Technology with Significant 2024 Milestones
TL;DR
Nutriband (NASDAQ: NTRB) anticipates $200M & $130M peak sales for AVERSA Fentanyl & Buprenorphine, targeting pivotal clinical trials and NDA filings.
Nutriband is advancing AVERSA technology with Kindeva Drug Delivery, transitioning from feasibility to commercial development, raising $8.4M in non-brokered placement.
Nutriband aims to prevent drug abuse through AVERSA technology, expanding global patent portfolio to 46 countries, expecting revenue growth from partnerships in 2025.
Nutriband raises $8.4M, expands global patent portfolio, and collaborates with Kindeva Drug Delivery to advance AVERSA technology and prevent drug abuse.
Found this article helpful?
Share it with your network and spread the knowledge!
Nutriband Inc., a pharmaceutical technology company, is making significant strides in developing abuse-deterrent transdermal drug delivery systems. Under the leadership of CEO Gareth Sheridan, the company has achieved key milestones in 2024 that position it for potential commercial success in 2025.
The company's primary focus is its AVERSA technology, which aims to prevent drug abuse, misuse, diversion, and accidental exposure in transdermal patches. Nutriband is currently developing two primary products: AVERSA Fentanyl and AVERSA Buprenorphine, with projected peak annual sales of $200 million and $130 million, respectively.
In partnership with Kindeva Drug Delivery, Nutriband is preparing for a pivotal Human Abuse Liability clinical trial and plans to file a New Drug Application (NDA). This strategic collaboration represents a critical step in commercializing its innovative drug delivery technology.
The company has also expanded its global intellectual property footprint, securing patents in 46 countries. Additionally, Nutriband raised $8.4 million through a non-brokered placement, providing financial resources to support its development initiatives.
The organization anticipates continued revenue growth in 2025 through its Pocono Pharma subsidiary, which has established a partnership with KT Tape. These developments underscore Nutriband's commitment to developing safer pharmaceutical technologies that address critical challenges in drug delivery and abuse prevention.
Curated from InvestorBrandNetwork (IBN)
